Boreal Genomics Announces Early Access Program for OnTarget™ Allele Enrichment System
Los Altos, CA – February 16, 2012
Sensitive detection of rare somatic mutations by highly selective wild-type allele depletion
Boreal Genomics, a developer of sequence-based enrichment technology, introduced the OnTarget™ Allele Enrichment System today through an early access program. The OnTarget™ System utilizes Boreal’s novel technology for the depletion of wild-type alleles with single nucleotide selectivity for improved detection of both known and unknown rare cancer mutations.
OnTarget™ enables clinicians and oncology researchers to enrich rare cancer mutations at frequencies down to 0.01% from plasma, frozen or FFPE tissues in less than 2 hours. Early access to this transformative technology will enable customers to develop highly sensitive oncology assays to guide clinical decisions during targeted therapy regimens. Furthermore, accurate and sensitive monitoring will promote early therapeutic decisions when treatment should be altered due to emergence of drug resistance.
“This is a significant milestone for Boreal Genomics and we are very excited to contribute to efforts aimed at improving monitoring and early detection of cancer”, said Nitin Sood, Chief Executive Officer at Boreal Genomics.
In preparation for a wider release of the OnTarget™ System, Boreal will be working alongside researchers at Stanford University to evaluate improvements to the detection of cancer mutations in heterogeneous tumor tissue where the majority of isolated DNA does not originate from the tumor.
Boreal is currently accepting pre-orders for the OnTarget™ System with units planned for shipment in mid-2012. This week’s AGBT conference will feature a presentation by Dr. Andre Marziali titled “Multiplexed Enrichment of Rare Alleles” which will discuss the technology and applications of the OnTarget™ Platform.
For more information please visit http://www.borealgenomics.com
